14.02.2022 • Whitepaper

Solvent Abatement and VOC Recovery for Pharmaceutical Manufacturers

Learn about the merits of cryo condensation and its unique sustainability for the pharmaceutical industry.

The pharmaceutical industry is currently making strenuous efforts to reduce its impact on the environment. Such efforts necessarily intensify the scrutiny of emissions from pharmaceutical manufacturing processes along with the impact of associated mitigation technology. Optimising solvent abatement and volatile organic compound (VOC) recovery processes is a small but important part of the overall challenge and calls for reliable, cost-effective solutions with a low environmental footprint.

This whitepaper introduces the Cryo-Condap system, a cryogenic solvent abatement and VOC recovery technology from Air Products with proven application in the pharmaceutical industry. It examines the technology's merits relative to alternative technologies within the context of ‘Net Zero’ solvent abatement and VOC recovery. A case study illustrates the application of the Cryo-Condap technology to reduce VOC emissions at a biopharmaceutical site to levels far below those specified by the EPA and at the same time eliminate the production of waste carbon.

Download the Whitepaper here.

 

 

 

 

 

 

 

 

 

 

 Sponsored by


Company

Logo:

Air Products & Chem. Inc.

7201 Hamilton Blvd.
PA 18195 Allentown
US

Company contact







Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read